ArticleFrontiers in cardiovascular medicine2025
Echocardiographic assessment of the relationship between cardiac function and plasma homocysteine levels in patients with heart failure and preserved ejection fraction.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The plasma protein profile of left ventricular diastolic function.Scientific reports · 2026Article
- Development and external validation of a sarcopenia risk prediction model in elderly patients with heart failure with preserved ejection fraction.BMC geriatrics · 2026Article
- Abdominal Obesity, Hepatic Steatosis, Oxidative Stress and Diastolic Dysfunction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is characterized by normal ejection fraction and diastolic dysfunction. The role of plasma homocysteine (Hcy) levels in HFpEF has been understudied, though elevated levels are known to affect cardiovascular health. Methods: This retrospective observational study analyzed 80 HFpEF patients and 80 matched controls without HFpEF. Fasting plasma Hcy levels were measured using a dual-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Standard echocardiographic evaluations were performed to measure interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left atrial diameter (LAD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and the early-to-late diastolic mitral inflow velocity ratio (E/A). Statistical analyses included independent sample t-tests, chi-square tests, Pearson's correlation, and Spearman's rank correlation. Results: HFpEF patients exhibited significantly higher plasma Hcy levels (45.17 µmol/L) compared with controls (33.85 µmol/L, Conclusions: The findings indicate that elevated plasma homocysteine is associated with myocardial remodeling and impaired diastolic function in HFpEF patients. These results support the potential role of homocysteine as a biomarker for HFpEF severity and progression, warranting further investigation into its utility for risk stratification and targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.